Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
177
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 42 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 5, 2024 | Denosumab | FDA US | cancer not stated in this record | Efficacy supplement 2024-03-05 (see label) | SUPPLBLA125320 | approved | openfda |
| Mar 1, 2024 | Amivantamab | FDA US | cancer not stated in this record | Efficacy supplement 2024-03-01 (see label) | SUPPLBLA761210 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | Teclistamab | FDA US | cancer not stated in this record | Efficacy supplement 2024-02-20 (see label) | SUPPLBLA761291 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 31, 2024 | Osimertinib Mesylate | FDA US | cancer not stated in this record | Efficacy supplement 2024-01-31 (see label) | SUPPLNDA208065 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 21, 2023 | Zanubrutinib | FDA US | cancer not stated in this record | Efficacy supplement 2023-12-21 (see label) | SUPPLNDA213217 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 27, 2023 | Nirogacestat | FDA US | cancer not stated in this record | OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment. OGSIVEO is a gamma secretase… | ORIG |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 31, 2023 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2023-10-31 (see label) | SUPPLBLA125514 | approved | openfda |
| Oct 31, 2023 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| Feb 16, 2024 | Osimertinib Mesylate | FDA US | cancer not stated in this record | Efficacy supplement 2024-02-16 (see label) | SUPPLNDA208065 | approved | openfda |
| Feb 16, 2024 | Osimertinib | FDA US | cancer not stated in this record | Efficacy supplement 2024-02-16 (see label) | SUPPLNDA208065 | approved | openfda |
| Feb 15, 2024 | Trastuzumab Deruxtecan | FDA US | cancer not stated in this record | Efficacy supplement 2024-02-15 (see label) | SUPPLBLA761139 | approved | openfda |
| Feb 15, 2024 | Trastuzumab Deruxtecan | FDA US | cancer not stated in this record | Efficacy supplement 2024-02-15 (see label) | SUPPLBLA761139 | approved | openfda |
| Feb 15, 2024 | Tepotinib | FDA US | cancer not stated in this record | Efficacy supplement 2024-02-15 (see label) | SUPPLNDA214096 | approved | openfda |
| Feb 13, 2024 | Irinotecan | FDA US | cancer not stated in this record | Efficacy supplement 2024-02-13 (see label) | SUPPLNDA207793 | approved | openfda |
| Jan 31, 2024 | Osimertinib | FDA US | cancer not stated in this record | Efficacy supplement 2024-01-31 (see label) | SUPPLNDA208065 | approved | openfda |
| Jan 26, 2024 | Nivolumab | FDA US | cancer not stated in this record | Efficacy supplement 2024-01-26 (see label) | SUPPLBLA125554 | approved | openfda |
| Jan 25, 2024 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2024-01-25 (see label) | SUPPLBLA125514 | approved | openfda |
| Jan 24, 2024 | Selumetinib | FDA US | cancer not stated in this record | Efficacy supplement 2024-01-24 (see label) | SUPPLNDA213756 | approved | openfda |
| Jan 19, 2024 | Erdafitinib | FDA US | cancer not stated in this record | Efficacy supplement 2024-01-19 (see label) | SUPPLNDA212018 | approved | openfda |
| Jan 19, 2024 | Erdafitinib | FDA US | cancer not stated in this record | Efficacy supplement 2024-01-19 (see label) | SUPPLNDA212018 | approved | openfda |
| Jan 18, 2024 | Alpelisib | FDA US | cancer not stated in this record | Efficacy supplement 2024-01-18 (see label) | SUPPLNDA212526 | approved | openfda |
| Jan 12, 2024 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2024-01-12 (see label) | SUPPLBLA125514 | approved | openfda |
| Dec 19, 2023 | Apalutamide | FDA US | cancer not stated in this record | Efficacy supplement 2023-12-19 (see label) | SUPPLNDA210951 | approved | openfda |
| Dec 15, 2023 | Roflumilast | FDA US | cancer not stated in this record | ZORYVE topical foam, 0.3%, is a phosphodiesterase 4 inhibitor indicated for the treatment of seborrheic dermatitis in adult and pediatric… | ORIGNDA217242 | approved | openfda |
| Dec 15, 2023 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2023-12-15 (see label) | SUPPLBLA125514 | approved | openfda |
| Dec 15, 2023 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2023-12-15 (see label) | SUPPLBLA125514 | approved | openfda |
| Dec 15, 2023 | Enfortumab Vedotin | FDA US | cancer not stated in this record | Efficacy supplement 2023-12-15 (see label) | SUPPLBLA761137 | approved | openfda |
| Dec 15, 2023 | Enfortumab Vedotin | FDA US | cancer not stated in this record | Efficacy supplement 2023-12-15 (see label) | SUPPLBLA761137 | approved | openfda |
| Dec 14, 2023 | Belzutifan | FDA US | cancer not stated in this record | Efficacy supplement 2023-12-14 (see label) | SUPPLNDA215383 | approved | openfda |
| Dec 11, 2023 | Peginterferon Alfa-2a | FDA US | cancer not stated in this record | Efficacy supplement 2023-12-11 (see label) | SUPPLBLA103964 | approved | openfda |
| Dec 5, 2023 | Dasatinib | FDA US | cancer not stated in this record | 1. INDICATIONS AND USAGE PHYRAGO is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive… | ORIGNDA216099 | approved | openfda |
| Dec 1, 2023 | Pirtobrutinib | FDA US | cancer not stated in this record | Efficacy supplement 2023-12-01 (see label) | SUPPLNDA216059 | approved | openfda |
| approved |
| openfda |
| Nov 21, 2023 | Paclitaxel | FDA US | cancer not stated in this record | Efficacy supplement 2023-11-21 (see label) | SUPPLNDA216338 | approved | openfda |
| Nov 16, 2023 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2023-11-16 (see label) | SUPPLBLA125514 | approved | openfda |
| Nov 16, 2023 | Enzalutamide | FDA US | cancer not stated in this record | Efficacy supplement 2023-11-16 (see label) | SUPPLNDA213674 | approved | openfda |
| Nov 16, 2023 | Enzalutamide | FDA US | cancer not stated in this record | Efficacy supplement 2023-11-16 (see label) | SUPPLNDA203415 | approved | openfda |
| Nov 16, 2023 | Capivasertib | FDA US | Malignant Prostate Neoplasm | PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer • in combination with abiraterone and… | ORIGNDA218197 | approved | openfda |
| Nov 16, 2023 | Capivasertib | FDA US | Malignant Breast Neoplasm | HR positive, HER2 negative locally advanced or metastatic breast cancer • in combination with fulvestrant for the treatment of adult… | ORIGNDA218197 | approved | openfda |
| Nov 15, 2023 | Repotrectinib | FDA US | Tumor-agnostic | adult and pediatric patients 12 years of age and older with solid tumors that: • have a neurotrophic tyrosine receptor kinase ( NTRK ) gene… | ORIGNDA218213 | approved | openfda |
| Nov 15, 2023 | Repotrectinib | FDA US | ROS1-Positive Lung Non-Small Cell Carcinoma | AUGTYRO is a kinase inhibitor indicated for the treatment of • adult patients with locally advanced or metastatic ROS1- positive non-small… | ORIGNDA218213 | approved | openfda |
| Nov 8, 2023 | Fruquintinib | FDA US | Malignant Colorectal Neoplasm | 1. INDICATIONS AND USAGE FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been… | ORIGNDA217564 | approved | openfda |
| Nov 7, 2023 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2023-11-07 (see label) | SUPPLBLA125514 | approved | openfda |
| Nov 6, 2023 | Olaparib | FDA US | cancer not stated in this record | Efficacy supplement 2023-11-06 (see label) | SUPPLNDA208558 | approved | openfda |
| Nov 1, 2023 | Isatuximab | FDA US | cancer not stated in this record | Efficacy supplement 2023-11-01 (see label) | SUPPLBLA761113 | approved | openfda |
| Pembrolizumab |
| FDA US |
| cancer not stated in this record |
| Efficacy supplement 2023-10-31 (see label) |
| SUPPLBLA125514 |
| approved |
| openfda |
| Oct 27, 2023 | Toripalimab | FDA US | cancer not stated in this record | as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a… | ORIGBLA761240 | approved | openfda |
| Oct 27, 2023 | Toripalimab | FDA US | Nasopharyngeal Carcinoma | in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced… | ORIGBLA761240 | approved | openfda |
| Oct 24, 2023 | Ivosidenib | FDA US | cancer not stated in this record | Efficacy supplement 2023-10-24 (see label) | SUPPLNDA211192 | approved | openfda |
| Oct 23, 2023 | Pembrolizumab | FDA US | cancer not stated in this record | Efficacy supplement 2023-10-23 (see label) | SUPPLBLA125514 | approved | openfda |
| Oct 23, 2023 | Lenvatinib | FDA US | cancer not stated in this record | Efficacy supplement 2023-10-23 (see label) | SUPPLNDA206947 | approved | openfda |
| Oct 20, 2023 | Entrectinib | FDA US | Tumor-agnostic | Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene… | ORIGNDA218550 | approved | openfda |